RxDoctor Payments Data

Edwin Cabahug

Family · Bakersfield, CANPI 1972055952

Payments from drug & device makers

$2,543in general payments, 2019–2025

Across 55 payments — averaging $46.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$376
  • GSK$293
  • Amgen$276
  • Novo Nordisk$266
  • E.r. Squibb & Sons, L.L.C.$195
  • AstraZeneca$153
  • plus $984 from 12 others

What the payments were for

  • Food & beverage$2,543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,543 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$3,963
Medicare patients
86
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$29,832
OzempicSemaglutide17$15,167
Albuterol Sulfate HfaAlbuterol Sulfate43$1,174
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,003
Omega-3 Acid Ethyl Esters20$952
Atorvastatin Calcium149$896
Diclofenac Sodium19$681
Gabapentin26$480
Lisinopril107$410
Losartan Potassium77$346
Tamsulosin Hcl15$335
Omeprazole42$285
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst28$257
Fluticasone Propionate29$225
Metformin Hcl66$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$266$15,16717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →